Meeting
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Authors
Gregory J. Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Gregory J. Riely , Egbert F. Smit , Myung-Ju Ahn , Enriqueta Felip , Suresh S. Ramalingam , Anne S. Tsao , Melissa Lynne Johnson , Francesco Gelsomino , Raymond M. Esper , Ernest Nadal , Michael Offin , Mariano Provencio-Pulla , Gregory Alan Otterson , Ibiayi Dagogo-Jack , Ann Alcasid , Tiziana Usari , Keith D. Wilner , Nuzhat Pathan , Bruce E. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03915951
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9018)
DOI
10.1200/JCO.2023.41.16_suppl.9018
Abstract #
9018
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.
First Author: David Planchard
Poster
2023 ASCO Annual Meeting
Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).
First Author: Makoto Tahara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.
First Author: Yungchang Chen
Poster
2019 ASCO Annual Meeting
Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
First Author: Nong Xu